Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bright Minds Biosciences Inc. before investing.

In this article, we go over a few key elements for understanding Bright Minds Biosciences Inc.’s stock price such as:

• Bright Minds Biosciences Inc.’s current stock price and volume
• Why Bright Minds Biosciences Inc.’s stock price changed recently
• Upgrades and downgrades for DRUG from analysts
• DRUG’s stock price momentum as measured by its relative strength

About Bright Minds Biosciences Inc. (DRUG)

Before we jump into Bright Minds Biosciences Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Want to learn more about Bright Minds Biosciences Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bright Minds Biosciences Inc..

Bright Minds Biosciences Inc.’s Stock Price as of Market Close

As of February 26, 2026, 12:07 PM, CST, Bright Minds Biosciences Inc.’s stock price was $87.370.

Bright Minds Biosciences Inc. is down 2.92% from its previous closing price of $90.000.

During the last market session, Bright Minds Biosciences Inc.’s stock traded between $87.050 and $90.950. Currently, there are approximately 5.66 million shares outstanding for Bright Minds Biosciences Inc..

Bright Minds Biosciences Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Bright Minds Biosciences Inc. Stock Price History

Bright Minds Biosciences Inc.’s (DRUG) price is currently up 12.37% so far this month.

During the month of February, Bright Minds Biosciences Inc.’s stock price has reached a high of $91.000 and a low of $72.075.

Over the last year, Bright Minds Biosciences Inc. has hit prices as high as $123.750 and as low as $23.175. Year to date, Bright Minds Biosciences Inc.’s stock is up 11.96%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bright Minds Biosciences Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 25, 2026, there was 1 analyst who downgraded Bright Minds Biosciences Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Bright Minds Biosciences Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bright Minds Biosciences Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bright Minds Biosciences Inc. (DRUG) by visiting AAII Stock Evaluator.

Relative Price Strength of Bright Minds Biosciences Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 25, 2026, Bright Minds Biosciences Inc. has a weighted four-quarter relative price strength of 29.63%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Bright Minds Biosciences Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bright Minds Biosciences Inc. Stock Price: Bottom Line

As of February 26, 2026, Bright Minds Biosciences Inc.’s stock price is $87.370, which is down 2.92% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bright Minds Biosciences Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.